高リン血症治療の世界市場レポート 2025年

高リン血症治療の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR13.7％で85億6,000万米ドルに成長します。予測期間の成長は、高リン血症の原因となる生活習慣病の増加、高齢化人口の継続的な増加、高リン血症に対する認識と診断の高まり、疾病負担の大きい新興市場の拡大、新興国におけるカルシウム系リン酸結合剤の処方シェアの上昇などに起因すると考えられます。予測期間における主な動向としては、高リン血症治療技術の進歩、遠隔医療と遠隔患者モニタリングの統合、研究開発のための共同研究およびパートナーシップ、高リン血症における患者教育とライフスタイル管理の重視、新規リン酸結合剤および治療法の開発などが挙げられます。

高リン血症治療市場の成長を後押ししているのは、長期的なケアを必要とする慢性疾患の患者数の増加です。心血管疾患、慢性腎臓病、慢性呼吸器疾患、副甲状腺機能亢進症、糖尿病、がんなどの慢性疾患は、2023年9月に世界保健機関（WHO）が報告したように、世界の死因のかなりの部分を占めており、74％が非感染性疾患（NCDs）または慢性疾患に起因しています。2023年2月にSingleCare Services LLCが発表したところによると、腎臓病は増加傾向にあり、未治療の腎不全が毎年約100万人の命を奪っています。末期腎不全（ESRD）患者における高リン血症の症例の増加が、高リン血症治療医薬品の需要を牽引しています。

食事療法の増加は、高リン血症治療市場の今後の成長を促進すると予想されています。食事療法とは、特定の健康、栄養、ライフスタイルの目標を達成するために、食習慣や食事内容を意図的に変更することを指します。これらの変更は、高リン血症の管理に大きく役立ち、リン酸値のコントロール、合併症の予防、薬物への依存度の低減、全体的な健康の促進、生活の質の向上に役立ちます。例えば、米国を拠点とする組織である国際食品情報評議会は、2023年に、特定の食事パターンまたは食事療法に従っている団塊世代の数が顕著に増加し、その数値は2022年の29％から41％に上昇したと報告しています。したがって、食生活の改善傾向の高まりが高リン血症治療市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界成長分析と戦略分析フレームワーク

• 世界の高リン血症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の高リン血症治療市場成長率分析
• 世界の高リン血症治療市場の実績：規模と成長, 2019-2024
• 世界の高リン血症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の高リン血症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の高リン血症治療市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• セベラマー
• カルシウム系リン酸結合剤
• 鉄系リン酸結合剤
• 炭酸ランタン
• その他の製品
• 世界の高リン血症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンラインストア
• 世界の高リン血症治療市場：セベラマーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• セベラマー塩酸塩
• セベラマー炭酸塩
• 世界の高リン血症治療市場：カルシウム系リン酸結合剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酢酸カルシウム
• 炭酸カルシウム
• 世界の高リン血症治療市場：鉄系リン酸バインダーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クエン酸第二鉄
• 硫酸鉄
• 世界の高リン血症治療市場：炭酸ランタンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 炭酸ランタン水和物
• 世界の高リン血症治療市場：その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• マグネシウム系リン酸結合剤
• 新規リン酸結合剤

第7章 地域別・国別分析

• 世界の高リン血症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の高リン血症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 高リン血症治療市場：競合情勢
• 高リン血症治療市場：企業プロファイル
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Akebia Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Ardelyx Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Medical Care AG & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Ultragenyx Pharmaceutical Inc.
• Unicycive Therapeutics Inc.
• Vifor Pharma Management Ltd.
• Zeria Pharmaceutical Co. Ltd.
• Amgen Inc.
• AstraZeneca plc
• Baxter International Inc.
• Beckman Coulter Inc.
• Cleveland Clinic
• DaVita Inc.
• Kyowa Kirin Pharmaceuticals Co. Ltd.
• Mayo Clinic

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 高リン血症治療市場2029年-最も新しい機会を提供する国
• 高リン血症治療市場2029年-最も新しい機会を提供するセグメント
• 高リン血症治療市場2029年-成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hyperphosphatemia treatment involves a class of drugs designed to enhance renal excretion for managing patients with elevated levels of phosphates. The most effective method is through volume replenishment using saline and forced diuresis with a loop diuretic such as furosemide or bumetanide.

The primary products in the hyperphosphatemia treatment market include sevelamer, calcium-based phosphate binders, iron-based phosphate binders, lanthanum carbonate, and others. The sevelamer market comprises sales of sevelamer products by entities (organizations, partnerships, and sole traders). Sevelamer is a phosphate-binding medication used to treat hyperphosphatemia in patients with chronic kidney diseases. The distribution of hyperphosphatemia treatment occurs through various channels, including hospital pharmacies, retail pharmacies, and online stores. In terms of dosage form, it is segmented into capsules, tablets, and syrups.

The hyperphosphatemia treatment market research report is one of a series of new reports from The Business Research Company that provides hyperphosphatemia treatment market statistics, including hyperphosphatemia treatment industry global market size, regional shares, competitors with a hyperphosphatemia treatment market share, detailed hyperphosphatemia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hyperphosphatemia treatment industry. This hyperphosphatemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperphosphatemia treatment market size has grown rapidly in recent years. It will grow from $4.56 billion in 2024 to $5.13 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to increased incidence of chronic kidney disease (CKD), growth in aging population, high prevalence of diabetes and hypertension, expansion of dialysis patient population, advances in medical research and diagnosis of hyperphosphatemia.

The hyperphosphatemia treatment market size is expected to see rapid growth in the next few years. It will grow to $8.56 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to rise in lifestyle-related diseases contributing to hyperphosphatemia, continued growth in aging demographics, increasing awareness and diagnosis of hyperphosphatemia, expansion of emerging markets with high disease burden, higher prescription share of calcium-based phosphate binders in emerging countries. Major trends in the forecast period include advancements in hyperphosphatemia treatment technologies, integration of telehealth and remote patient monitoring, collaborations and partnerships for research and development, focus on patient education and lifestyle management in hyperphosphatemia, development of novel phosphate binders and therapies.

The growth of the hyperphosphatemia treatment market is being fueled by the increasing prevalence of chronic diseases among patients, which require long-term care. Chronic diseases, including cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer, contribute to a significant portion of global deaths, with 74% attributed to non-communicable diseases (NCDs) or chronic diseases, as reported by the World Health Organization in September 2023. Notably, kidney diseases are on the rise, with untreated kidney failure claiming the lives of approximately 1 million individuals each year, according to SingleCare Services LLC in February 2023. The escalating cases of hyperphosphatemia in patients with end-stage renal disease (ESRD) are driving the demand for hyperphosphatemia treatment drugs.

The rise in dietary modifications is anticipated to drive the growth of the hyperphosphatemia treatment market in the future. Dietary modifications refer to intentional alterations made to a person's eating habits or diet to achieve specific health, nutritional, or lifestyle objectives. These modifications can significantly aid in managing hyperphosphatemia, helping to control phosphate levels, prevent complications, reduce reliance on medication, promote overall health, and enhance quality of life. For example, in 2023, the International Food Information Council, a US-based organization, reported a notable increase in the number of boomers following specific eating patterns or diets, with the figure rising to 41%, up from 29% in 2022. Therefore, the growing trend of dietary modifications is fueling the expansion of the hyperphosphatemia treatment market.

The growing emphasis on research and development activities is a significant trend in the hyperphosphatemia treatment market. Companies involved in hyperphosphatemia treatment are concentrating on R&D to create innovative therapies for renal diseases and associated chronic conditions. For example, in April 2024, Eurostat, a European governmental agency, reported that in 2023, the Ile-de-France region in France had 2.4 million core human resources dedicated to science and technology, the highest number in Europe. The Comunidad de Madrid region in Spain followed with 1.2 million.

Major companies in the hyperphosphatemia treatment market are concentrating on the development of innovative products, such as Xphozah, to drive market revenues. Xphozah, designed to treat hyperphosphatemia, addresses the excessive phosphorus causing calcium removal from bones and various body parts. In October 2023, Ardelyx Inc., a US-based biopharmaceutical company, received FDA approval for Xphozah. This approval is for the treatment of hyperphosphatemia in patients unresponsive or intolerant to current standard-of-care phosphate binder therapies.

In May 2023, South Africa-based healthcare services group Life Healthcare Group Holdings Limited acquired Fresenius Medical Care AG and Co. KGaA for an undisclosed amount. This strategic acquisition enhances Life Healthcare's offerings in acute and ongoing renal dialysis treatments in South Africa. With the acquisition, Life Healthcare aims to play a vital role in ensuring the continuity of existing patient care plans. Fresenius Medical Care AG and Co. KGaA, a Germany-based company manufacturing hyperphosphatemia treatment drugs, is now part of Life Healthcare Group Holdings Limited.

Major companies operating in the hyperphosphatemia treatment market include Sanofi SA, Akebia Therapeutics Inc., Ardelyx Inc., Astellas Pharma Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Unicycive Therapeutics Inc., Vifor Pharma Management Ltd., Zeria Pharmaceutical Co. Ltd., Amgen Inc., AstraZeneca plc, Baxter International Inc., Beckman Coulter Inc., Cleveland Clinic, DaVita Inc., Kyowa Kirin Pharmaceuticals Co. Ltd., Mayo Clinic, OPKO Health Inc., Tenet Healthcare Corporation, UnitedHealth Group Inc.

North America was the largest region in the hyperphosphatemia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperphosphatemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hyperphosphatemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The hyperphosphatemia treatment market includes revenues earned by lowering the phosphate load and maintaining serum phosphorus levels within the normal range. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hyperphosphatemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hyperphosphatemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hyperphosphatemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hyperphosphatemia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Sevelamer; Calcium-Based Phosphate Binders; Iron-Based Phosphate Binders; Lanthanum Carbonate; Other products
• 2) By Distribution channel: Hospital Pharmacy; Retail Pharmacy; Online stores
• Subsegments:
• 1) By Sevelamer: Sevelamer Hydrochloride; Sevelamer Carbonate
• 2) By Calcium-Based Phosphate Binders: Calcium Acetate; Calcium Carbonate
• 3) By Iron-Based Phosphate Binders: Ferric Citrate; Ferric Sulfate
• 4) By Lanthanum Carbonate: Lanthanum Carbonate Hydrate
• 5) By Other Products: Magnesium-Based Phosphate Binders; Novel Phosphate Binders
• Companies Mentioned: Sanofi SA; Akebia Therapeutics Inc.; Ardelyx Inc.; Astellas Pharma Inc.; Fresenius Medical Care AG & Co. KGaA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hyperphosphatemia Treatment Market Characteristics

3. Hyperphosphatemia Treatment Market Trends And Strategies

4. Hyperphosphatemia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hyperphosphatemia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hyperphosphatemia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hyperphosphatemia Treatment Market Growth Rate Analysis
• 5.4. Global Hyperphosphatemia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hyperphosphatemia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hyperphosphatemia Treatment Total Addressable Market (TAM)

6. Hyperphosphatemia Treatment Market Segmentation

• 6.1. Global Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sevelamer
• Calcium-Based Phosphate Binders
• Iron-Based Phosphate Binders
• Lanthanum Carbonate
• Other products
• 6.2. Global Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online stores
• 6.3. Global Hyperphosphatemia Treatment Market, Sub-Segmentation Of Sevelamer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sevelamer Hydrochloride
• Sevelamer Carbonate
• 6.4. Global Hyperphosphatemia Treatment Market, Sub-Segmentation Of Calcium-Based Phosphate Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcium Acetate
• Calcium Carbonate
• 6.5. Global Hyperphosphatemia Treatment Market, Sub-Segmentation Of Iron-Based Phosphate Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ferric Citrate
• Ferric Sulfate
• 6.6. Global Hyperphosphatemia Treatment Market, Sub-Segmentation Of Lanthanum Carbonate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lanthanum Carbonate Hydrate
• 6.7. Global Hyperphosphatemia Treatment Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Magnesium-Based Phosphate Binders
• Novel Phosphate Binders

7. Hyperphosphatemia Treatment Market Regional And Country Analysis

• 7.1. Global Hyperphosphatemia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hyperphosphatemia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hyperphosphatemia Treatment Market

• 8.1. Asia-Pacific Hyperphosphatemia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hyperphosphatemia Treatment Market

• 9.1. China Hyperphosphatemia Treatment Market Overview
• 9.2. China Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hyperphosphatemia Treatment Market

• 10.1. India Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hyperphosphatemia Treatment Market

• 11.1. Japan Hyperphosphatemia Treatment Market Overview
• 11.2. Japan Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hyperphosphatemia Treatment Market

• 12.1. Australia Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hyperphosphatemia Treatment Market

• 13.1. Indonesia Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hyperphosphatemia Treatment Market

• 14.1. South Korea Hyperphosphatemia Treatment Market Overview
• 14.2. South Korea Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hyperphosphatemia Treatment Market

• 15.1. Western Europe Hyperphosphatemia Treatment Market Overview
• 15.2. Western Europe Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hyperphosphatemia Treatment Market

• 16.1. UK Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hyperphosphatemia Treatment Market

• 17.1. Germany Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hyperphosphatemia Treatment Market

• 18.1. France Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hyperphosphatemia Treatment Market

• 19.1. Italy Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hyperphosphatemia Treatment Market

• 20.1. Spain Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hyperphosphatemia Treatment Market

• 21.1. Eastern Europe Hyperphosphatemia Treatment Market Overview
• 21.2. Eastern Europe Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hyperphosphatemia Treatment Market

• 22.1. Russia Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hyperphosphatemia Treatment Market

• 23.1. North America Hyperphosphatemia Treatment Market Overview
• 23.2. North America Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hyperphosphatemia Treatment Market

• 24.1. USA Hyperphosphatemia Treatment Market Overview
• 24.2. USA Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hyperphosphatemia Treatment Market

• 25.1. Canada Hyperphosphatemia Treatment Market Overview
• 25.2. Canada Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hyperphosphatemia Treatment Market

• 26.1. South America Hyperphosphatemia Treatment Market Overview
• 26.2. South America Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hyperphosphatemia Treatment Market

• 27.1. Brazil Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hyperphosphatemia Treatment Market

• 28.1. Middle East Hyperphosphatemia Treatment Market Overview
• 28.2. Middle East Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hyperphosphatemia Treatment Market

• 29.1. Africa Hyperphosphatemia Treatment Market Overview
• 29.2. Africa Hyperphosphatemia Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hyperphosphatemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hyperphosphatemia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Hyperphosphatemia Treatment Market Competitive Landscape
• 30.2. Hyperphosphatemia Treatment Market Company Profiles
  • 30.2.1. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Akebia Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Ardelyx Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Medical Care AG & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis

31. Hyperphosphatemia Treatment Market Other Major And Innovative Companies

• 31.1. Lupin Limited
• 31.2. Sun Pharmaceutical Industries Ltd.
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Ultragenyx Pharmaceutical Inc.
• 31.5. Unicycive Therapeutics Inc.
• 31.6. Vifor Pharma Management Ltd.
• 31.7. Zeria Pharmaceutical Co. Ltd.
• 31.8. Amgen Inc.
• 31.9. AstraZeneca plc
• 31.10. Baxter International Inc.
• 31.11. Beckman Coulter Inc.
• 31.12. Cleveland Clinic
• 31.13. DaVita Inc.
• 31.14. Kyowa Kirin Pharmaceuticals Co. Ltd.
• 31.15. Mayo Clinic

32. Global Hyperphosphatemia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hyperphosphatemia Treatment Market

34. Recent Developments In The Hyperphosphatemia Treatment Market

35. Hyperphosphatemia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Hyperphosphatemia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hyperphosphatemia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hyperphosphatemia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer